Canopy Growth (CGC) Non-Current Deferred Tax Liability (2017 - 2026)
Canopy Growth (CGC) posted Non-Current Deferred Tax Liability of $6.0 million for Q1 2026, up 569.26% sequentially from $893343.0 in Q2 2023.
Canopy Growth (CGC) Non-Current Deferred Tax Liability (2017 - 2026) Analysis & Trends
Canopy Growth has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $6.0 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (changed N/A YoY) and the FY2026 annual result came in at $6.0 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability climbed to $6.0 million in Q1 2026 per CGC's latest filing, from $893343.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $12.6 million in Q1 2022 and troughed at $264071.6 in Q1 2023.
- A 3-year average of $6.5 million and a median of $6.6 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability declined 25.26% in 2022, then sank 97.91% in 2023.
- Over 3 years, Non-Current Deferred Tax Liability stood at $6.6 million in 2022, then tumbled by 86.51% to $893343.0 in 2023, then surged by 569.26% to $6.0 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $6.0 million, $893343.0, and $264071.6 for Q1 2026, Q2 2023, and Q1 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Canopy Growth | 437.04 Mn | 190.03 Mn | 16.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.72 Mn |
| Jun 30, 2026 | 5.72 Mn |
| Mar 31, 2026 | 5.98 Mn |
| Mar 31, 2026 | 5.98 Mn |
| Jun 30, 2023 | 893,342.96 |
| Jun 30, 2023 | 893,342.96 |
| Mar 31, 2023 | 264,071.60 |
| Mar 31, 2023 | 264,071.60 |
| Dec 31, 2022 | 6.62 Mn |
| Dec 31, 2022 | 6.62 Mn |
| Sep 30, 2022 | 7.48 Mn |
| Sep 30, 2022 | 7.48 Mn |
| Jun 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 11.50 Mn |
| Mar 31, 2022 | 12.62 Mn |
| Mar 31, 2022 | 12.62 Mn |
| Dec 31, 2021 | 21.71 Mn |
| Dec 31, 2021 | 21.71 Mn |
| Sep 30, 2021 | 20.23 Mn |
| Sep 30, 2021 | 20.23 Mn |